Small Cell Lung Carcinoma
Conditions
Keywords
Extensive stage small cell lung cancer
Brief summary
This study is designed to evaluate the safety and tolerability of durvalumab and tremelimumab in combination with intravenous (IV) carboplatin plus (+) etoposide in new patients with extensive-stage small cell lung cancer (ES-SCLC).
Detailed description
This Phase I, multicenter, study is designed to evaluate the safety and tolerability of durvalumab (anti-programmed death-ligand 1 \[PD-L1\] antibody) and tremelimumab (anti-cytotoxic T-lymphocyte-associated protein 4 \[CTLA-4\] antibody) in combination with intravenous (IV) carboplatin plus (+) etoposide in treatment naïve patients with extensive-stage small cell lung cancer (ES-SCLC) and performance status 2 (PS2). Eighteen patients with untreated ES-SCLC and PS2 will be enrolled. Cohort 1, which includes the first 6 subjects, will receive IV carboplatin and etoposide Q 3 weeks x 4 cycles. Durvalumab 1500 mg IV Q 3 weeks will be given with chemotherapy during cycles 3 and 4. This will be followed by durvalumab 1500 mg IV Q 4 weeks until disease progression. If 2 out of 6 patients have dose-limiting toxicities, then the study will be closed. Cohort 2, which will include 12 additional subjects, will receive chemotherapy Q 3 weeks x 4 cycles. Durvalumab 1500 mg IV + tremelimumab 75 mg IV Q 3 weeks will be given with chemotherapy during cycles 3 and 4, then durvalumab 1500 mg + tremelimumab 75 mg will be administered Q 3 weeks during cycles 5 and 6. This will be followed by durvalumab 1500 mg IV Q 4 weeks until disease progression.
Interventions
COMBINATION_PRODUCTDurvalumab + Tremelimumab in combination with carboplatin and etoposide
1500mg of durvalumab plus 75mg of tremelimumab in combination with carboplatin and etoposide will be given every 3 weeks for Cycles 3 and 4. 1500mg of durvalumab plus 75mg of tremelimumab will be given every 3 weeks for Cycles 5 and 6.
COMBINATION_PRODUCTDurvalumab in combination with carboplatin and etoposide
1500mg of durvalumab in combination with carboplatin and etoposide will be given every 3 weeks for Cycles 3 and 4.
Sponsors
AstraZeneca
University of Nebraska
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years old at time of study entry (consent) and adult male or female (For Nebraska, ≥19 years old) 2. Histologically or cytologically confirmed ES-SCLC 3. Tumor biopsy or cytology should be obtained within 8 weeks of initiation of treatment. 4. Brain metastases; must be asymptomatic or treated and stable, off steroids for at least 1 month prior to study treatment. 5. Have not received any prior therapy for SCLC, except palliative radiation. If the patient received radiation, there must be measurable disease outside the radiation field. 6. Measurable disease or evaluable disease based on RECIST Version 1.1. 7. Eastern Cooperative Oncology Group ECOG = 2 8. Body weight \> 30 kg 9. No active secondary malignancy. Patients with other prior malignancies will be included, provided they have been disease-free for at least five years. 10. Adequate hematologic and end organ function 11. Women of childbearing potential must have a pregnancy test (urine or serum) proven negative within 14 days prior to registration.
Exclusion criteria
1. Participation in another clinical study with an investigational product during the last 28 days. 2. Any previous chemotherapy and /or immunotherapy for SCLC 3. Current or prior use (≤ 14 days before first doses of study drugs) of immunosuppressive medication. 4. Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment. 5. History of another primary malignancy except for malignancy treated with curative intent and with no known active disease ≥5 years before the first dose of IP 6. History of leptomeningeal carcinomatosis 7. Paraneoplastic syndrome (PNS) of autoimmune nature, requiring systemic steroids or clinical symptomatology suggesting worsening of PNS 8. Active infection including tuberculosis, HIV, hepatitis B and C. 9. Active or prior documented autoimmune or inflammatory disorders 10. Uncontrolled cardiovascular disease 11. History of active primary immunodeficiency 12. Pregnant or lactating women 13. Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Treatment-related Adverse Events with a Severity of 3 or higher (Safety and tolerability) | 3 months | Evaluate the safety and tolerability profile of durvalumab + tremelimumab in combination with carboplatin and etoposide in ES-SCLC and PS2. Adverse events with a severity grade of 3 or higher per CTCAE guidelines will be used to assess this outcome. |
Countries
United States
Outcome results
None listed